Literature DB >> 20585121

Synergy of caspofungin with human polymorphonuclear granulocytes for killing Candida albicans.

Vivian Tullio1, Narcisa Mandras, Daniela Scalas, Valeria Allizond, Giuliana Banche, Janira Roana, Deborah Greco, Franco Castagno, Anna Maria Cuffini, Nicola A Carlone.   

Abstract

The influence of caspofungin on polymorphonuclear leukocyte (PMN) phagocytosis and intracellular killing of Candida albicans was investigated. Caspofungin, at all of the concentrations tested (2, 3.2, and 8 microg/ml), significantly increased intracellular killing by PMNs through its direct action on both yeast cells and PMNs, indicating the potential ability of caspofungin to synergize with phagocytes for candidal killing. Caspofungin may therefore constitute an effective therapeutic option for the treatment of invasive fungal infections, including those refractory to conventional treatment with azole agents.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20585121      PMCID： PMC2934974          DOI： 10.1128/AAC.01780-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Combined action of fluconazole and PMNs from uremic patients in clearing intracellular Candida albicans.

Authors:  V Tullio; A M Cuffini; F Giacchino; N Mandras; J Roana; L Comune; C Merlino; N A Carlone
Journal:  J Chemother       Date:  2003-06       Impact factor: 1.714

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 3.  Immunocompromised hosts: immunopharmacology of modern antifungals.

Authors:  R Ben-Ami; R E Lewis; D P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2008-07-15       Impact factor: 9.079

4.  The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus.

Authors:  T Chiller; K Farrokhshad; E Brummer; D A Stevens
Journal:  Diagn Microbiol Infect Dis       Date:  2001-02       Impact factor: 2.803

5.  Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Authors:  Julie A Stone; Sherry D Holland; Peter J Wickersham; Andrew Sterrett; Michael Schwartz; Cynthia Bonfiglio; Michael Hesney; Gregory A Winchell; Paul J Deutsch; Howard Greenberg; Thomas L Hunt; Scott A Waldman
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 6.  Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.

Authors:  A H Groll; T J Walsh
Journal:  Expert Opin Investig Drugs       Date:  2001-08       Impact factor: 6.206

Review 7.  Caspofungin: the first representative of a new antifungal class.

Authors:  Valérie Letscher-Bru; Raoul Herbrecht
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

8.  Influence of thiamphenicol on the primary functions of human polymorphonuclear leucocytes against Streptococcus pyogenes.

Authors:  Vivian Tullio; Annamaria Cuffini; Narcisa Mandras; Janira Roana; Giuliana Banche; Domenico Ungheri; Nicola Carlone
Journal:  Int J Antimicrob Agents       Date:  2004-10       Impact factor: 5.283

9.  Caspofungin.

Authors:  Stanley C Deresinski; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079

10.  Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes.

Authors:  U Frank; M Greiner; I Engels; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-06       Impact factor: 3.267
View more
  5 in total

1.  Candida albicans infections in renal transplant recipients: effect of caspofungin on polymorphonuclear cells.

Authors:  Valeria Allizond; Giuliana Banche; Franca Giacchino; Chiara Merlino; Daniela Scalas; Vivian Tullio; Giuseppe Garneri; Narcisa Mandras; Janira Roana; Anna Maria Cuffini
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

2.  Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors.

Authors:  Chantal Fernandes; Jorge Anjos; Louise A Walker; Branca M A Silva; Luísa Cortes; Marta Mota; Carol A Munro; Neil A R Gow; Teresa Gonçalves
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

3.  Antifungal Drugs Influence Neutrophil Effector Functions.

Authors:  Frederic Ries; Astrid Alflen; Pamela Aranda Lopez; Hendrik Beckert; Matthias Theobald; Hansjörg Schild; Daniel Teschner; Markus Philipp Radsak
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Interaction of platelets and anidulafungin against Aspergillus fumigatus.

Authors:  Susanne Perkhofer; Barbara Striessnig; Bettina Sartori; Barbara Hausott; Helmut W Ott; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

5.  Enhanced Killing of Candida krusei by Polymorphonuclear Leucocytes in the Presence of Subinhibitory Concentrations of Melaleuca alternifolia and "Mentha of Pancalieri" Essential Oils.

Authors:  Vivian Tullio; Janira Roana; Daniela Scalas; Narcisa Mandras
Journal:  Molecules       Date:  2019-10-23       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.